New perspectives for chronic pain treatment: a patent review (2010-2016)

References

• Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Prepared by the International Association for the Study of Pain, Subcommittee on Taxonomy. Pain Suppl. 1986;3:S1–S226.
   PubMedGoogle Scholar
• Ernst FR, Mills JR, Berner T, et al. Opioid medication practices observed in chronic pain patients presenting for all-causes to emergency departments: prevalence and impact on health care outcomes. J Manag Care Spec Pharm. 2015;21:925–936.
   PubMed Web of Science ®Google Scholar
• Gaskin DJ, Richard P. The economic costs of pain in the United States. J Pain Off J Am Pain Soc. 2012;13:715–724.
   PubMed Web of Science ®Google Scholar
• Burma NE, Leduc-Pessah H, Fan CY, et al. Animal models of chronic pain: advances and challenges for clinical translation. J Neurosci Res. 2016 [cited 4 Jul 2016]. DOI: 10.1002/jnr.23768
   PubMed Web of Science ®Google Scholar
• Loeser JD, Treede R-D. The Kyoto protocol of IASP basic pain terminology. Pain. 2008;137:473–477.
   PubMed Web of Science ®Google Scholar
• Ji -R-R, Xu -Z-Z, Gao Y-J. Emerging targets in neuroinflammation-driven chronic pain. Nat Rev Drug Discov. 2014;13:533–548.
   PubMed Web of Science ®Google Scholar
• Millan MJ. Descending control of pain. Prog Neurobiol. 2002;66:355–474.
   PubMed Web of Science ®Google Scholar
• Okuse K. Pain signalling pathways: from cytokines to ion channels. Int J Biochem Cell Biol. 2007;39:490–496.
   PubMed Web of Science ®Google Scholar
• Starowicz K, Przewlocka B. Modulation of neuropathic-pain-related behaviour by the spinal endocannabinoid/endovanilloid system. Phil Trans R Soc B. 2012;367:3286–3299.
   PubMed Web of Science ®Google Scholar
• Kim J, Song S, Lee I, et al. Anti-inflammatory activity of constituents from Glechoma hederacea var. Longituba Bioorg Med Chem Lett. 2011;21:3483–3487.
   PubMed Web of Science ®Google Scholar
• Tyagi N, Goel R. Models for neuropathic pain: a review. Int J Pharm Pharm Sci. 2014;6:36–39.
   Google Scholar
• Wall PD, Devor M, Inbal R, et al. Autotomy following peripheral nerve lesions: experimental anaesthesia dolorosa. Pain. 1979;7:103–111.
   PubMed Web of Science ®Google Scholar
• Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain. 1988;33:87–107.
   PubMed Web of Science ®Google Scholar
• Seltzer Z, Dubner R, Shir Y. A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain. 1990;43:205–218.
   PubMed Web of Science ®Google Scholar
• Zhang R-X, Ren K. Animal models of pain. Totowa: Humana Press; 2011.
   Google Scholar
• Iadarola MJ, Brady LS, Draisci G, et al. Enhancement of dynorphin gene expression in spinal cord following experimental inflammation: stimulus specificity, behavioral parameters and opioid receptor binding. Pain. 1988;35:313–326.
   PubMed Web of Science ®Google Scholar
• Millan MJ, Członkowski A, Morris B, et al. Inflammation of the hind limb as a model of unilateral, localized pain: influence on multiple opioid systems in the spinal cord of the rat. Pain. 1988;35:299–312.
   PubMed Web of Science ®Google Scholar
• Lao L, Zhang R-X, Zhang G, et al. A parametric study of electroacupuncture on persistent hyperalgesia and Fos protein expression in rats. Brain Res. 2004;1020:18–29.
   PubMed Web of Science ®Google Scholar
• Sandkuhler J. Models and mechanisms of hyperalgesia and allodynia. Physiol Rev. 2009;89:707–758.
   PubMed Web of Science ®Google Scholar
• Barrot M. Tests and models of nociception and pain in rodents. Neuroscience. 2012;211:39–50.
   PubMed Web of Science ®Google Scholar
• Long SA, Meyers MJ, Pelc MJ, et al. 7-Azaspiro[3.5]nonane-7-carboxamide compounds. US0113465. 2010.
   Google Scholar
• van der Stelt M, Barbara Cals JMG. 1-(Biphenyl-4-ylmethyl)imidazolidine-2,4-dione. US0144723. 2010.
   Google Scholar
• Manzanares J, Julian M, Carrascosa A. Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. Curr Neuropharmacol. 2006;4:239–257.
   PubMed Web of Science ®Google Scholar
• Liang S, Xu C, Gao Y, et al. Application of puerarin in the preparation of p2x3 mediated drugs for pain/nervous system diseases. US0152205. 2011.
   Google Scholar
• North RA. P2X3 receptors and peripheral pain mechanisms. J Physiol. 2004;554:301–308.
   PubMed Web of Science ®Google Scholar
• Kandula M. 2, 6 Xylidine derivatives for the treatment of pain. US0172421. 2012.
   Google Scholar
• Salvemini D, Neumann WL, Rausaria S. Method for treating chronic pain. US0135973. 2012.
   Google Scholar
• Linz K, Zemolka S, Nolte B, et al. Cis-tetrahydro-spiro(cyclohexane-1,1ʹ-pyrido[3,4-b]indole)-4-amine Compounds. US0029006. 2012.
   Google Scholar
• Tibbs GR, Flood P, Goldstein P. Compositions and methods of treating chronic pain by administering propofol derivatives. US0005718. 2013.
   Google Scholar
• Ehring G, Chao E, Ng H, et al. Benzimidazole derivatives as selective blockers of persistent sodium current. WO101911. 2013.
   Google Scholar
• Lee DH Novel benzamide derivative and use thereof. US0336378. 2014.
   Google Scholar
• Abbott FV, Hong Y, Blier P. Activation of 5-HT2A receptors potentiates pain produced by inflammatory mediators. Neuropharmacology. 1996;35:99–110.
   PubMed Web of Science ®Google Scholar
• Higashiyama H, Kazuta Y, Hashimoto K. Therapeutic and/or preventive agent comprising 1-indansulfamide derivative for pain. WO093515. 2015.
   Google Scholar
• Barker O, Bently JM, Bock MG, et al. Triazine-oxadiazoles. US0025057. 2015.
   Google Scholar
• Gil DW. Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol. US0080445. 2015.
   Google Scholar
• Kandula M. Compositions and methods for the treatment of neurological conditions. US0119452. 2015.
   Google Scholar
• Pacheco O, Garcia A, Oliveira K, et al. Heteroaromatic compounds, method for preparing the compounds, pharmaceutical compositions, uses and method for treating acute and chronic pain. US0266864. 2015.
   Google Scholar
• Kiso T, Tsukamoto M. Triazole Derivative for use in the treatment of neuropathic pain and fibromyalgia. EP2614824. 2015.
   Google Scholar
• Kandula M. Dithiolan-3-ylpentanoate derivatives, pharmaceutical compositions and methods for the treatment of pain. WO118554. 2015.
   Google Scholar
• Leuwer M, O’neill P, Berry N, et al. Pharmacologically active compounds. WO097475. 2015.
   Google Scholar
• Lynch JW, Callister RJ. Glycine receptors: a new therapeutic target in pain pathways. Curr Opin Investig Drugs Lond Engl. 2000;2006(7):48–53.
   Google Scholar
• Cheng X, Mei F, Kavelaars A, et al. Methods and compositions for treating chronic pain. US0263088. 2016. 43.
   Google Scholar
• Nahin RL. Estimates of pain prevalence and severity in adults: United States, 2012. J Pain. 2015;16:769–780.
   PubMed Web of Science ®Google Scholar
• Ten Kate K, Laird SA. The commercial use of biodiversity: access to genetic resources and benefit-sharing. London: Earthscan Publications; 1999.
   Google Scholar
• Laffleur F. Mucoadhesive therapeutic compositions: a patent review (2011–2014). Expert Opin Ther Pat. 2016;26:377–388.
   PubMed Web of Science ®Google Scholar
• Brito RG, Araújo AAS, Quintans JSS, et al. Enhanced analgesic activity by cyclodextrins – a systematic review and meta-analysis. Expert Opin Drug Deliv. 2015;12:1677–1688.
   PubMed Web of Science ®Google Scholar